Zoekresultaten - You searched for Stock Market?type=newsArticle

40 results

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Read more

Suspension of trading in Ablynx shares on Euronext Brussels

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)

Read more

Bone Therapeutics Launches Equity Placement

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

Bone Therapeutics announces private placement of convertible bonds

Read more

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

Read more

Galapagos creates new warrant plan

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

flanders.bio Ghent becomes biotechnology capital of europe

Read more

ThromboGenics becomes "Oxurion"

Read more

Biocartis Creates New Warrant Plan

Read more

argenx reports third quarter 2018 financial results and provides business update

Read more

500 vacancies in the Flemish biotech sector

Read more

Galapagos creates new warrant plan

Read more

Ablynx: publication in accordance with article 14 of the Belgian law regarding the publication of major shareholdings

Read more

Biocartis announces H1 2017 results

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

MDxHealth Notice of Financial Year 2017 Results

Read more

MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

Read more

MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

Read more

MDxHealth's SelectMDx Test Successfully Stratifies Men

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Read more

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Website

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

argenx files registration statement for a proposed public offering in the United States

Read more

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Read more

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix

Read more

Mithra to Initiate PK Study for Estelle®

Read more

argenx announces launch of proposed initial public offering in the United States

Read more

argenx announces size of initial public offering in the United States increased to 5 million ADSs

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more